New pill ZT006 aims to shed pounds in obesity trial

NCT ID NCT07230132

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a new tablet, ZT006, for weight loss in 184 overweight or obese adults. Participants take either ZT006 or a placebo daily for 28 weeks, with the dose slowly increased to help tolerance. The main goal is to see how much weight people lose. This is a Phase 2 trial, meaning it's still early in testing for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT/OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250000, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 030001, China

  • Handan First Hospital

    Handan, Hebei, 056002, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, 150001, China

  • Hebei Petro China Cental Hospital

    Langfang, Hebei, 065000, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, 471002, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210003, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, 710000, China

  • YueYang People's Hospital

    Yueyang, Hunan, 414022, China

Conditions

Explore the condition pages connected to this study.